Phytobacterium plantarum and application thereof in fermentation of sophora flowers for relieving hyperuricemia

Abstract

The invention discloses a plant lactobacillus and an application thereof in fermentation of sophora flowers for relieving hyperuricemia. The name of the lactobacillus plantarum is lactobacillus plantarum WH-JS4, the lactobacillus plantarum WH-JS4 is preserved in Guangdong Microbial Culture Collection Center on November 7, 2024, and the preservation number of the lactobacillus plantarum WH-JS4 is GDMCC No: 65437, the GDMCC No: 65437. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The plant lactobacillus WH-JS4 can be used for sophora flower fermentation, sophora flower fermentation liquor obtained through fermentation has a good uric acid reducing effect, and the plant lactobacillus WH-JS4 can be used for developing functional products for preventing or treating hyperuricemia.

Description

Technical Field

[0001] The present invention belongs to the technical field of fermentation engineering, and particularly relates to a Lactiplantibacillus plantarum and its application in fermenting sophora flower to relieve hyperuricemia. Background Art

[0002] Worldwide, the prevalence of hyperuricemia has been increasing year by year, and the age of onset is tending to be younger. Hyperuricemia has now been recognized as the second most common chronic disease after type 2 diabetes, posing a serious threat to human health and the public health system. Hyperuricemia is a disorder of uric acid metabolism, where the synthesis of uric acid is excessive or the excretion is insufficient, thus causing an increase in the uric acid level in the body. Currently, the main treatment strategies for hyperuricemia include dietary intervention and drug treatment. Although clinical drugs such as allopurinol, febuxostat, probenecid, and lesinurad can relieve hyperuricemia, long-term use may cause serious side effects such as allergies, rashes, and liver and kidney damage. In terms of dietary intervention, a low-purine diet is commonly used to treat hyperuricemia, but its efficacy and patient compliance are usually poor. Therefore, it is particularly important to develop a safe and effective treatment strategy for hyperuricemia.

[0003] In the field of natural resources, especially substances homologous in medicine and food, they have attracted increasing attention and research due to their natural properties, low toxicity, and rich in various active ingredients. For example, substances homologous in medicine and food such as sophora flower, astragalus root, chicory, coix seed, and chrysanthemum all show the potential to relieve hyperuricemia. Sophora flower, as the dried flower buds of the leguminous plant Sophora japonica, not only has a long history of medicinal and edible use, but also contains rich active ingredients such as flavonoids, triterpenoids, saponins, and alkaloids, and has various biological activities such as antibacterial, anti-inflammatory, antioxidant, and anti-obesity. Existing research shows that sophora flower has xanthine oxidase inhibitory activity and antioxidant activity, revealing its significant potential in reducing uric acid.

[0004] However, substances homologous in medicine and food such as sophora flower have limitations such as large molecular weight, large volume, low bioavailability, and poor taste, which limit their wide application in practice. Fortunately, the development of probiotic fermentation technology provides a new solution for the high-value utilization and industrialization of substances homologous in medicine and food. Research also found that substances homologous in medicine and food exert their active effects by acting on the human gut microbiota. The fermentation process mediated by some probiotics can release or transform the active ingredients in substances such as sophora flower, thereby enhancing or improving their active effects. Therefore, exploring whether probiotic-fermented sophora flower can reduce the uric acid level has important research value and application prospects. Summary of the Invention

[0005] The primary object of the present invention is to overcome the deficiencies of the prior art and provide a Lactiplantibacillus plantarum.

[0006] Another object of the present invention is to provide the application of the Lactiplantibacillus plantarum in the fermentation of Sophora japonica flowers.

[0007] Yet another object of the present invention is to provide a method for preparing a Sophora japonica flower fermentation broth with the function of preventing and / or treating hyperuricemia.

[0008] The objects of the present invention are achieved by the following technical solutions:

[0009] A strain of Lactiplantibacillus plantarum, named Lactiplantibacillus plantarum WH-JS4, was deposited on November 7, 2024 at the Guangdong Provincial Microbial Culture Collection Center (GDMCC), 5th Floor, Building 59, No. 100, Middle Xianlie Road, Guangzhou, with the deposit number: GDMCC No: 65437.

[0010] The application of the above-mentioned Lactiplantibacillus plantarum in the fermentation of Sophora japonica flowers.

[0011] A method for preparing a Sophora japonica flower fermentation broth with the function of preventing and / or treating hyperuricemia, comprising the following steps:

[0012] (1) After removing impurities from Sophora japonica flowers, they are dried, crushed and sieved to obtain Sophora japonica flower powder; then water is added and mixed evenly, and sterilization is carried out to obtain a fermentation substrate;

[0013] (2) The above-mentioned Lactiplantibacillus plantarum is inoculated into the fermentation substrate and fermented at 25-40 °C. After the fermentation is completed, centrifugation is carried out to obtain a Sophora japonica flower fermentation broth.

[0014] The Sophora japonica flowers described in step (1) are preferably Sophora japonica var. japonica.

[0015] The sieving described in step (1) is through a 50-100 mesh sieve; preferably through a 100 mesh sieve.

[0016] The ratio of the Sophora japonica flower powder to water in step (1) is 1 g:(10-50) mL; preferably 1 g:10 mL.

[0017] The sterilization described in step (1) is high-temperature sterilization, with a temperature of 90-121 °C (preferably 121 °C) and a time of 15-30 minutes (preferably 15 minutes).

[0018] In step (2), the Lactiplantibacillus plantarum is a strain after activation culture, and its preparation method is as follows: The Lactiplantibacillus plantarum is inoculated into MRS liquid medium and continuously activated three times, and statically cultured at 25-40 °C (preferably 37 °C) for 6-72 hours (preferably 24 hours), and then resuspended with sterile water to obtain a Lactiplantibacillus plantarum seed solution.

[0019] The inoculation amount of the Lactiplantibacillus plantarum described above is calculated by adding it at a final concentration of 1-5% by volume in the activation system; preferably, it is calculated by adding it at a final concentration of 2% by volume in the activation system.

[0020] In step (2), the inoculation amount of the Lactiplantibacillus plantarum described above is calculated by adding it at a final concentration of 10 6 ~10 8 CFU / mL in the fermentation system; preferably, it is calculated by adding it at a final concentration of 10 7 CFU / mL in the fermentation system.

[0021] In step (2), the fermentation temperature described above is preferably 37 °C.

[0022] In step (2), the fermentation time is 6-72 hours; preferably, it is 48 hours.

[0023] In step (2), the centrifugation conditions are: centrifuging at 4000-12000 rpm / min for 10-20 min; preferably: centrifuging at 12000 rpm / min for 15 min.

[0024] For the preparation method of the Sophora japonica fermentation broth with the function of preventing and / or treating hyperuricemia, after step (2), it may further include the step of subjecting the obtained Sophora japonica fermentation broth to membrane filtration.

[0025] The membrane filtration described above is carried out using a 0.22 μm filter membrane.

[0026] A Sophora japonica fermentation broth with the function of preventing and / or treating hyperuricemia is prepared by the method described in any one of the above.

[0027] Application of the Lactiplantibacillus plantarum and / or the Sophora japonica fermentation broth in the preparation of a product for preventing and / or treating (alleviating) hyperuricemia.

[0028] Application of the Lactiplantibacillus plantarum and / or the Sophora japonica fermentation broth in the preparation of a product for inhibiting xanthine oxidase.

[0029] The product described above includes a functional food or a drug.

[0030] The present invention has the following advantages and effects compared with the prior art:

[0031] 1. Through screening of xanthine oxidase (XOD), the present invention obtains a probiotic strain (Lactiplantibacillus plantarum WH-JS4) that can enhance the uric acid-lowering activity of Sophora japonica, and this strain can be used for fermenting Sophora japonica.

[0032] 2. The present invention constructs a hyperuricemia mouse model by intragastric administration of hypoxanthine and potassium oxonate, and intervenes with the fermentation broth of Sophora japonica fermented by probiotics. Analyze relevant indicators such as serum biochemical indexes, xanthine oxidase activity, renal oxidative stress, inflammation level, pathological damage and uric acid transporter genes of mice to evaluate its effect on improving hyperuricemia. The results show that after 14 days of intervention with the probiotic Sophora japonica fermentation broth, the uric acid level, serum creatinine and blood urea nitrogen in the serum of hyperuricemia mice can be restored to normal levels, and the activities of alanine aminotransferase and aspartate aminotransferase in the liver of hyperuricemic mice can be significantly reduced. At the same time, the xanthine oxidase activity levels in the serum and liver of mice can be reduced. In addition, the activities of superoxide dismutase (SOD), catalase (CAT) and antioxidant enzymes such as glutathione peroxidase (GSH-Px) in the kidneys of mice are significantly increased. The probiotic fermented Sophora japonica fermentation broth can significantly reduce the levels of pro-inflammatory factors IL-6 and TNF-α in the kidneys, and at the same time enhance the secretion of anti-inflammatory factor IL-10. Histopathology shows that the probiotic fermented Sophora japonica fermentation broth can significantly alleviate the kidney and jejunum damage of hyperuricemic mice. On the one hand, the probiotic fermented Sophora japonica fermentation broth can significantly reduce the protein expression of urate reabsorption transporter GLUT9 and URAT1 in the kidneys, and on the other hand, it can significantly increase the expression of uric acid secretion transporter ABCG2 in the kidneys and jejunum, thereby alleviating hyperuricemia.

[0033] 2. The probiotic fermented Sophora japonica fermentation broth prepared in the present invention has a good effect of reducing uric acid and can be used to prepare functional foods or drugs that inhibit xanthine oxidase and prevent and / or treat hyperuricemia. Description of the Drawings

[0034] Figure 1 Effect of probiotic fermented Sophora japonica on uric acid content in HK-2 cells (in the figure, the values are expressed as mean ± standard deviation (n = 6). Compared with the control group, ### p < 0.001; compared with the model group, * p < 0.05, ** p < 0.01, *** p < 0.001).

[0035] Figure 2 Effect of probiotic fermented Sophora japonica on the expression levels of adenosine deaminase (ADA), ABCG2 and GLUT9 genes in HK-2 cells (GADPH was used as an internal control. The values are expressed as mean ± standard deviation (n = 6). Compared with the control group, ### p < 0.001; compared with the model group, * p < 0.05, ** p < 0.01, ***p < 0.001); where (A) is adenosine deaminase (ADA); (B) is the expression level of ABCG2 gene; (C) is the expression level of GLUT9 gene.

[0036] Figure 3 Effect diagram of probiotic-fermented Sophora japonica flowers on the levels of blood uric acid, serum creatinine (CRE), blood urea nitrogen (BUN), serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) in hyperuricemic mice (all data in the figure are mean ± standard deviation. Compared with the control group, # p < 0.05, ## p < 0.01, ### p < 0.001; compared with the model group, * p < 0.05, ** p < 0.01); where (A) is blood uric acid; (B) is serum creatinine (CRE); (C) is blood urea nitrogen (BUN); (D) is serum alanine aminotransferase (ALT); (E) is serum aspartate aminotransferase (AST).

[0037] Figure 4 Effect diagram of probiotic-fermented Sophora japonica flowers on the activities of serum XOD and liver XOD in hyperuricemic mice (all data in the figure are mean ± standard deviation, compared with the control group, ### p < 0.001; compared with the model group, * p < 0.05, ** p < 0.01, *** p < 0.001); where (A) is serum XOD of hyperuricemic mice; (B) is liver XOD of hyperuricemic mice.

[0038] Figure 5 Effect diagram of probiotic-fermented Sophora japonica flowers on the antioxidant activities of SOD, CAT and GSH-Px in the kidneys of hyperuricemic mice (all data in the figure are mean ± standard deviation, compared with the control group, ### p < 0.001; compared with the model group, * p < 0.05, ** p < 0.01, *** p < 0.001; SOD: superoxide dismutase; CAT: catalase; GSH: glutathione); where (A) is kidney SOD; (B) is kidney CAT; (C) is kidney GSH-Px.

[0039] Figure 6 Effect diagram of fermented Sophora japonica flowers on the levels of IL-6, IL-10 and TNF-α in the kidneys of hyperuricemic mice (all data in the figure are mean ± standard deviation, compared with the control group, ### p < 0.001; compared with the model group, *p < 0.05, ** p < 0.01, *** p < 0.001); where (A) is IL-6; (B) is TNF-α; (C) is IL-10.

[0040] Figure 7 It is the staining result diagram of the pathological changes of the kidneys (Kidney) and jejunum (Jejunum) of hyperuricemia mice by fermented sophora japonica flowers (in the figure, Kidney, scale bar: 100 μm; original magnification 200 times; Jejunum, scale bar: 200 μm; original magnification 200 times).

[0041] Figure 8 It is the diagram of the effects of fermented sophora japonica flowers on the expression levels of kidney transporters (GLUT9, URAT1, ABCG2, and OAT1) and jejunum transporter (ABCG2) in hyperuricemia mice (in the figure, all data are mean ± standard deviation, compared with the control group, ### p < 0.001; compared with the model group, * p < 0.05, ** p < 0.01, *** p < 0.001); where (A) is kidney transporter GLUT9; (B) is kidney transporter URAT1; (C) is kidney transporter ABCG2; (D) is kidney transporter OAT1; (E) is jejunum transporter ABCG2.

[0042] Figure 9 It is the diagram of the effects of fermented sophora japonica flowers on the mRNA expression levels of kidney transporters (GLUT9, URAT1, ABCG2, and OAT1) and jejunum transporter (ABCG2) in hyperuricemia mice (in the figure, all data are mean ± standard deviation, compared with the control group, ### p < 0.001; compared with the model group, * p < 0.05, ** p < 0.01, *** p < 0.001); where (A) is kidney transporter GLUT9; (B) is kidney transporter URAT1; (C) is kidney transporter ABCG2; (D) is kidney transporter OAT1; (E) is jejunum transporter ABCG2;

[0043] Figure 10 It is the TIC diagram of the QC sample in positive ion mode and negative ion mode; where (A) is the positive ion mode; (B) is the negative ion mode.

[0044] Figure 11PCA score plots in positive ion mode and negative ion mode; among them, (A) is the positive ion mode; (B) is the negative ion mode.

[0045] Figure 12 OPLS-DA score plots and permutation test plots between the unfermented group and the fermented group in positive ion mode (A and C) (R2Y = 0.998, Q2 = 0.983) and negative ion mode (B and D) (R2Y = 0.999, Q2 = 0.98); among them, (A) is the OPLS-DA score plot in positive ion mode; (B) is the OPLS-DA score plot in negative ion mode; (C) is the permutation test plot in positive ion mode; (D) is the permutation test plot in negative ion mode.

[0046] Figure 13 Hierarchical clustering heat map of differential metabolites between the unfermented group and the fermented Sophora japonica group. Detailed implementation manners

[0047] The present invention will be further described in detail below in conjunction with embodiments, but the implementation manners of the present invention are not limited thereto. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the technical field. The test methods without specific experimental conditions in the following examples are usually carried out according to conventional experimental conditions or according to the experimental conditions recommended by the manufacturer. Unless otherwise specified, the reagents and raw materials used in the present invention can be obtained commercially.

[0048] Example 1 Screening of a strain enhancing the uric acid-lowering activity of Sophora japonica

[0049] (I) Isolation of strains

[0050] (1) Take 1 mL of fermented batter (from Tianshui, Gansu) and add it to 9 mL of sterile PBS buffer. After homogenizing and mixing evenly, perform gradient dilution in sequence, and then coat it on MRS solid medium containing 2% (w / v) CaCO 3 and incubate anaerobically at 37 °C for 36 - 48 h.

[0051] (2) Pick single colonies with obvious clear zones, smooth surfaces and circular shapes, number, record and purify by streaking at least 3 times. During the purification period, the strains can be preliminarily identified and contaminated bacteria can be removed according to their colony morphology, catalase test and Gram staining microscopy. Finally, inoculate the purified single colonies into MRS liquid medium and incubate statically at 37 °C for 18 h. Mix the fresh bacterial liquid with 25% (w / v) glycerol in equal volume and store it in a -80 °C refrigerator for later use.

[0052] (3) 17 strains were screened and named strain JS1 - JS17 respectively.

[0053] (2) Screening strains that can enhance the inhibitory activity of Sophora japonica flower against xanthine oxidase (XOD)

[0054] (1) Remove impurities from Sophora japonica flowers (commercially available), dry them, crush them into 100-mesh powder (pass through a 100-mesh sieve), mix evenly, add water at a material-liquid ratio of 1 g:10 mL, mix well, and sterilize at 121 °C for 15 minutes to obtain the fermentation substrate; after cooling to 25 °C, inoculate 17 probiotic strains (JS1-JS17) at a concentration of 10 7 CFU / mL, ferment statically at 37 °C for 48 h, centrifuge at 12000 rpm / min for 15 minutes, and filter through a 0.22-μm membrane to prepare the fermented Sophora japonica flower liquid by probiotics (100 mg / mL). Replace the probiotic strains with the same volume of sterile water, keep the other conditions unchanged, and the supernatant prepared is the unfermented Sophora japonica flower extract (Unfermented, 100 mg / mL).

[0055] (2) Set the reaction system to 200 μL. In a 96-well plate, add 60 μL of phosphate buffer (50 mM, pH = 7.5), 30 μL of xanthine oxidase (0.1 U / mL), and 50 μL of the sample solution (the fermented Sophora japonica flower liquid prepared in step (1)) in sequence. After mixing evenly, incubate at 37 °C for 15 min. Then add 60 μL of 0.15 mM xanthine to start the reaction, record the absorbance (As) at 295 nm and incubate for 5 minutes. The concentration of the sample solution in the reaction system is 100 μg / mL. The pH 7.5 phosphate buffer solution and allopurinol are used as the blank control and positive control respectively. Each sample is repeated three times. Calculate the inhibition rate of xanthine oxidase according to the following formula:

[0056]

[0057] where V 0 is the initial reaction rate of the enzyme system, and V S is the reaction rate of the enzyme system in the presence of the sample.

[0058] The inhibition rate increase of fermented Sophora japonica flower against xanthine oxidase is calculated using the following formula:

[0059]

[0060] where XO U is the inhibition rate of xanthine oxidase of unfermented Sophora japonica flower, and XO F is the inhibition rate of xanthine oxidase of fermented Sophora japonica flower.

[0061] (3) The experimental results are shown in Table 1. The inhibition rate of xanthine oxidase in Sophora japonica before fermentation was 63.0%. After fermentation with 17 strains, the inhibition rates of xanthine oxidase were 60.9% - 85.2%. Among them, the inhibition rate of the JS4 strain group was relatively the highest at 85.2%, followed by the JS6 strain group with an inhibition rate of 75.0%, and then the JS3 strain group with an inhibition rate of 72.6%. Considering comprehensively, strains JS3, JS4, and JS6 were selected for the next step of research.

[0062] Table 1 Inhibition rates of xanthine oxidase in Sophora japonica fermented by different probiotics

[0063]

[0064]

[0065] (III) Effects of probiotic fermentation strains on uric acid synthesis in HK-2 hyperuricemia model cells

[0066] (1) Effects of probiotic fermentation strains on uric acid production in HK-2 hyperuricemia model cells

[0067] The experimental groups were set as follows: 1) Control group: HK-2 cells (Haixing Biotechnology Co., Ltd., Suzhou, China) were treated with serum-free medium; 2) Model group: HK-2 cells were treated with serum-free medium containing 2.0 mM adenosine; 3) Allopurinol group: HK-2 cells were treated with serum-free medium containing 100 μmol / L allopurinol; 4) Unfermented Sophora japonica group: HK-2 cells were treated with serum-free medium containing unfermented Sophora japonica extract (1 mg / mL); 5) Fermented Sophora japonica group: HK-2 cells were treated with serum-free medium containing probiotic-fermented Sophora japonica fermentation broth (1 mg / mL). HK-2 cells were seeded into 6-well plates at a density of 2.5×10 5 cells / well and cultured at 37°C and 5% CO 2 for 12 h. Then the medium was removed, and the cells were washed twice with PBS. Serum-free medium, allopurinol, unfermented Sophora japonica, and fermented Sophora japonica were added respectively and incubated for 24 h. Then the medium was removed, and the cells were washed twice with PBS. Then serum-free medium containing 2.0 mM adenosine was added and cultured for 24 h. 0.005 U / mL xanthine oxidase was added to each well and cultured for another 8 h. After incubation, the cell supernatant was collected. The uric acid concentration in the cell supernatant of each group was measured using a uric acid assay kit (Nanjing Jiancheng Bioengineering Institute), and the experiment was set with 6 replicates.

[0068] The results are as Figure 1As shown, the results indicated that all three strains (JS3, JS4, and JS6) groups could significantly reduce the uric acid level in the model group, and the JS4 group had the best effect.

[0069] (2) Effects of probiotic fermentation strains on the gene expression levels of ADA, ABCG2, and GLUT9 in HK-2 hyperuricemic model cells

[0070] The HK-2 cells collected after the above-mentioned treatments in step (1) were rinsed with pre-cooled PBS, and the total RNA in the cells was extracted using a total RNA extraction kit (Vazyme Biotech Co., Ltd., Nanjing, China). The A260 / 280 ratio was measured using an ultra-micro spectrophotometer (K5600C, Kaiao Technology, Beijing) to determine the purity of the extracted RNA. Then, cDNA was synthesized using MightyScript FirstStrand cDNA Synthesis Master Mix, and qPCR reactions were performed using SGExcel FastSYBR Master (Sangon Biotech Co., Ltd., Shanghai). The thermal cycles of annealing and extension were carried out using a CFX96 real-time quantitative PCR instrument (Bio-Rad, USA). The instrument was heated to 95 °C and maintained for 3 minutes, and then cycled 40 times according to the following program: Finally, the relative gene expression levels were calculated using the 2 -ΔΔCt method. The primers used in this experiment were as follows:

[0071] GAPDH forward primer: 5'-TCCACTGGCGTCTTCACCACCAT-3' (SEQ ID NO.2);

[0072] GAPDH reverse primer: 5'-GGAGGCATTGCTGATGATCTTGAGG-3' (SEQ ID NO.3);

[0073] ADA forward primer: 5'-GCCTTCGACAAGCCCAAAGTA-3' (SEQ ID NO.4);

[0074] ADA reverse primer: 5'-CTCTGCTGTGTTAGCTGGGAG-3' (SEQ ID NO.5);

[0075] ABCG2 forward primer: 5'-ACGAACGGATTAACAGGGTCA-3' (SEQ ID NO.6);

[0076] ABCG2 reverse primer: 5'-CTCCAGACACCACGGAT-3' (SEQ ID NO.7);

[0077] GLUT9 forward primer: 5'-CAATAGACCCAGACACTCTGACT-3' (SEQ ID NO.8);

[0078] GLUT9 reverse primer: 5'-TCTTCACAATTAACGTCCCCAC-3' (SEQ ID NO.9).

[0079] The results were as Figure 2 shown. In groups JS3, JS4, and JS6, the mRNA expression levels of ADA and GLUT9 in the HK-2 cell model group were significantly decreased. In groups JS4 and JS6, the mRNA expression level of ABCG29 could be increased. Overall, the effect of group JS4 was the best. Therefore, strain JS4 was used for further research.

[0080] (IV) Molecular biological identification of the strain

[0081] (1) Using a DNA extraction kit (Sangon Biotech Co., Ltd., Shanghai), the genomic DNA of strain JS4 was extracted. According to the universal primers 27F and 1492R (27F: 5′-AGAGTTTGATCCTGGGCTCAG-3′ (SEQ ID NO.10); 1492R: 5′-GGTTACCTTGTTACGACTT-3′ (SEQ ID NO.11)), the 16S rDNA gene fragment of the strain was amplified, and the strain was identified and analyzed. The PCR amplification system consisted of 50 μL, including 1 μL of DNA template, 2 μL of primer F, 2 μL of primer R, 25 μL of 2×Taq PCR Master Mix, and 20 μL of ddH2O. The PCR program used in the experiment followed the established protocol: pre-denaturation at 94°C for 4 minutes, denaturation at 94°C for 30 seconds, annealing at 58°C for 30 seconds, extension at 72°C for 90 seconds. After 30 cycles, extension was carried out at 72°C for another 10 minutes. The amplified PCR product was sequenced, and homology search analysis was performed using nucleotide Blast in the NCBI database to determine the type of bacteria. Using MEGA 11.0 software, a phylogenetic tree was deduced by the neighbor-joining method, and the bootstrap value was set to 500.

[0082] (2) The nucleotides of the 16S rDNA of strain JS4 were subjected to homology comparison using the BLAST tool in the GenBank database of NCBI. It was found to be in the same branch as Lactiplantibacillus plantarum 3425 (accession number: MT505534.1) in Genbank, with a similarity of 99%. Strain JS4 was identified as Lactiplantibacillus plantarum. This strain was named Lactiplantibacillus plantarum WH-JS4 and was deposited on November 7, 2024, at the Guangdong Provincial Culture Collection Center of Microorganisms (GDMCC), Building 59, Yard 100, Xianlie Middle Road, Yuexiu District, Guangzhou, Guangdong Province, with the deposit number: GDMCC No: 65437.

[0083] The nucleotides of 16S rDNA (SEQ ID NO.1) are shown as follows:

[0084]

[0085] Example 2: Effects of Probiotic-fermented Sophora japonica Flower Fermentation Broth on Hyperuricemia Mice

[0086] (I) Preparation of Probiotic-fermented Sophora japonica Flower Fermentation Broth

[0087] After removing impurities, Sophora japonica flowers were dried and crushed into 100-mesh powder, mixed evenly, and mixed with water at a material-liquid ratio of 1 g: 10 mL, and sterilized at 121 °C for 15 minutes to obtain the fermentation substrate; after cooling to 25 °C, the Lactiplantibacillus plantarum WH-JS4 seed liquid was inoculated at a concentration of 10 7 CFU / mL, fermented statically at 37 °C for 48 h, centrifuged at 12000 rpm / min for 15 minutes, and filtered through a 0.22-μm membrane to prepare the probiotic-fermented Sophora japonica flower fermentation broth. The preparation method of the unfermented Sophora japonica flower extract (Unfermented) was the same as that in Example 1. Among them,

[0088] The preparation method of the Lactiplantibacillus plantarum WH-JS4 seed liquid was as follows: The Lactiplantibacillus plantarum WH-JS4 was inoculated into MRS liquid medium and continuously activated three times, inoculated into MRS liquid medium at an inoculation amount of 2% (v / v), and cultured statically at 37 °C for 24 h, and then resuspended with an equal volume of sterile water to obtain the Lactiplantibacillus plantarum WH-JS4 seed liquid (about 10 9 CFU / mL).

[0089] (II) The following experiments were carried out using the above-prepared probiotic-fermented Sophora japonica flower fermentation broth:

[0090] Forty SPF-grade male Kunming mice (18 - 22 g) were purchased from Guangdong Vital River Laboratory Animal Technology Co., Ltd. This experiment was carried out in the Experimental Animal Center of South China Agricultural University (License number: SYXK (Guangdong) 2022 - 0136), and the experimental process was carried out in accordance with the regulations on the management of laboratory animals of South China Agricultural University. Before the experiment, the animals were adaptively fed for one week in an SPF-grade animal house (25 ± 1 °C, relative humidity 60 ± 10%, 12 h light-dark cycle). The mice were randomly divided into 5 groups, namely the control group, the model group, the positive group (allopurinol, 10 mg / kg), the unfermented group (600 mg / kg), and the fermented group (600 mg / kg, JS4 group), with 8 experimental mice in each group. Except for the control group which was given 0.5% CMC-Na saline solution (weigh 0.5 g of dry carboxymethylcellulose sodium (CMC-Na, viscosity: 800 - 1200 mPa·s) and dissolve it in normal saline (0.9 g of NaCl dissolved in 100 ml of ddH2O) to make a clear solution), the other groups were administered orally by gavage with potassium oxonate (PO) (300 mg / kg) and hypoxanthine (HX) (300 mg / kg) once a day for 14 consecutive days to establish a hyperuricemia model. In addition, one hour after the administration of PO and HX, the positive group, the unfermented group, and the fermented group were treated with allopurinol, unfermented sophora japonica, and probiotic-fermented sophora japonica respectively for 14 days. Twelve hours before sacrifice, the animals were fasted but allowed to drink water. Serum samples were collected 1 hour after the last administration, and each organ was dissected and separated and weighed. Each organ was separated and stored for later use, and relevant data were measured.

[0091] (III) Effects of probiotic-fermented sophora japonica fermentation broth on hyperuricemic mice

[0092] 1. Effects of probiotic-fermented sophora japonica fermentation broth on the levels of serum uric acid, serum creatinine, blood urea nitrogen, serum alanine aminotransferase, and serum aspartate aminotransferase in hyperuricemic mice.

[0093] (1) The levels of serum uric acid, serum creatinine, blood urea nitrogen, serum alanine aminotransferase, and serum aspartate aminotransferase in mice were measured using kits (Nanjing Jiancheng). The experiment was set up with three replicates.

[0094] (2) After two weeks of combined intervention with hypoxanthine and potassium oxonate, compared with the control group, the serum uric acid level in the model group increased significantly to 195 μmol / L, and was significantly increased compared with the blank group (p < 0.001) Figure 3(A) therein, indicating the successful establishment of a hyperuricemia mouse model. The allopurinol group had the lowest uric acid level in the serum, only 36 μmol / L, which might be related to its inhibition of uric acid production. It is worth noting that the serum uric acid level of the JS4 group was significantly decreased to 85 μmol / L. Similarly, a decrease in the serum uric acid level of the unfermented group was also observed, but it was not statistically significant. Hyperuricemia is usually accompanied by kidney damage. We used serum biochemical indicators to study the effect of probiotic-fermented Sophora japonica on the renal function of hyperuricemic mice. As Figure 3 shown in (B) and (C) therein, compared with the blank group, the levels of CRE and BUN in the model group were significantly increased (p < 0.05). After allopurinol intervention, the levels of CRE and BUN were further increased (p < 0.001). Compared with the model group, except for the unfermented group, the JS4 group could significantly reduce the CRE level ( Figure 3 (B) therein). For the BUN level, no difference was found among the model group, the unfermented group, and the fermented groups ( Figure 3 (C) therein). ALT and AST are key indicators reflecting liver health status. As Figure 3 shown in (D) and (E) therein, compared with the control group, the activity levels of serum ALT and AST in the model group were significantly increased (p < 0.001). Compared with the model group, there was no significant difference in the activity levels of ALT and AST between the allopurinol group and the unfermented group, while the activity levels of ALT and AST in the JS4 group were significantly decreased.

[0095] 2. Effect of probiotic-fermented Sophora japonica fermentation broth on xanthine oxidase (XOD) in the serum and liver of hyperuricemic mice

[0096] (1) The xanthine oxidase activity in the serum and liver of mice was measured using a kit (Nanjing Jiancheng). The experiment was set up with three replicates.

[0097] (2) Xanthine oxidase is a key enzyme for purine metabolism to produce uric acid, which can catalyze the oxidation of hypoxanthine to xanthine and further catalyze the oxidation of xanthine to uric acid. As Figure 4 shown, there was a significant difference in XOD activity between the control group and the model group. Compared with the control group, the XOD activities in the serum and liver of the model group increased by 53.4% and 37.3% respectively. Compared with the model group, the allopurinol group decreased the XOD activity levels in the serum and liver by 45.3% and 24% respectively. It is worth noting that the JS4 group decreased the XOD activity levels in the serum and liver by 21.9% and 21.6% respectively. However, the unfermented Sophora japonica group had no significant effect on the XOD activity level in the liver and could significantly reduce the serum XOD activity level, but the degree of reduction was less than that of the JS4 group.

[0098] 3. Effects of Probiotic Fermented Sophora japonica Flower Fermentation Broth on the Enzyme Activities of Superoxide Dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GSH-Px) in the Kidneys of Hyperuricemia Mice

[0099] (1) The oxidative stress levels in the supernatant of mouse brain tissue homogenate were measured using a commercial kit, including the activities of SOD, CAT and GSH-Px. The tissue samples were homogenized in an ice bath with the extraction solution at a ratio of 1:9 (g / mL), centrifuged at 12,000 rpm and 4 °C for 10 min, and the supernatant was taken to detect the total protein content through a BCA kit. Subsequently, the oxidative stress indicators were detected strictly according to the kit instructions. The experiment was set up with three replicates.

[0100] (2) SOD, CAT and GSH-Px are important antioxidant enzymes in the body, which can block the damage of oxygen free radicals to cells and protect the body from oxidative stress damage. To study the effect of probiotic fermented Sophora japonica on renal oxidative stress in hyperuricemia mice, the activities of SOD, CAT and GSH-Px in the kidneys of mice were measured ( Figure 5 in (A), (B) and (C) of

[0101] ). Compared with the control group, the activities of SOD, CAT and GSH-Px in the kidneys of the model group mice were significantly decreased. In addition, after allopurinol treatment, their activities were further decreased. This indicates that high uric acid levels and allopurinol cause oxidative stress in the kidneys of mice. It is worth noting that the JS4 group reversed the decrease in the activities of SOD, CAT and GSH-Px in the kidneys of hyperuricemic mice and restored them to no significant difference from the control group. However, compared with the model group, the unfermented group did not show a significant improvement in the activities of SOD, CAT and GSH-Px in the kidneys of hyperuricemic mice.

[0102] (1) Mouse kidney samples were extracted with 9 volumes of PBS (v / w). After centrifugation for 20 min (12,000 rpm, 4 °C), the supernatant was collected, and the levels of related inflammatory cytokines interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor necrosis factor α (TNF-α) were detected using an ELISA kit. The experiment was set up with three replicates.

[0103] (2) Previous studies have confirmed the link between hyperuricemia and kidney inflammation, leading to severe kidney damage. Prolonged high uric acid levels can induce immune system activation and cytokine release, such as cytokines IL-6 and TNF-α, promoting inflammatory responses and further inducing kidney injury. Therefore, the effect of probiotic fermented Sophora japonica on kidney inflammation in hyperuricemia mice was evaluated. As Figure 6As shown, the contents of pro-inflammatory factors IL-6 and TNF-α in the kidneys of the model group were significantly higher than those of the control group (p<0.01). On the contrary, the content of anti-inflammatory factor IL-10 was significantly decreased (p<0.05). Compared with the model group, unfermented Sophora japonica can reduce the levels of IL-6 and TNF-α and increase the level of IL-10, but there was no significant difference in TNF-α and IL-10 statistically. The JS4 group can significantly reduce the levels of IL-6 and TNF-α in the kidneys. In addition, IL-10 in the kidneys was significantly increased under the intervention of the JS4 group, which was significantly stronger than that of the allopurinol group. Therefore, the JS4-fermented Sophora japonica group can effectively alleviate the immune inflammatory response in hyperuricemic mice.

[0104] 5. Effects of Fermented Liquid of Probiotics-fermented Sophora japonica on Histopathology of Hyperuricemic Mice

[0105] (1) The kidneys and jejunum tissues of mice were fixed with 4% paraformaldehyde for 24 h, dehydrated in a gradient of alcohol, cleared in xylene, and embedded in paraffin to make paraffin sections. Then hematoxylin-eosin (HE) staining was performed. Then the stained sections were dehydrated, cleared, and sealed. Finally, the tissues were examined under an optical microscope (200×), and then images were collected.

[0106] (2) As Figure 7 shown, compared with the blank group, the model group showed mild renal tubular dilation, exfoliation of renal epithelial cells, and glomerular swelling. After treatment with allopurinol, compared with the model group, the renal tubules of mice were further dilated, indicating that allopurinol may cause renal injury in mice. After treatment with probiotics-fermented Sophora japonica in hyperuricemic mice, the epithelial cells were arranged neatly, and the structures of renal tubules and glomeruli were normal, comparable to those of the blank group. The unfermented group showed that the epithelial cells were arranged neatly, but compared with the blank group, there was still mild dilation of the renal tubules. The results of HE staining in the jejunum showed that the mucosal structure of the jejunum in the blank group was intact, the villi were arranged neatly, and the intestinal glands were regular in shape. Compared with the blank group, the height of the villi in the model group was significantly decreased, there was less infiltration of inflammatory cells, and there were red staining granules in the stroma. Columnar epithelial necrosis and blurred striated border could be observed. Columnar epithelial hyperplasia began in the allopurinol group, and the intestinal mucosal villi increased. The intestinal mucosal villi increased in the unfermented group, but the villus structure was still incomplete. Compared with the model group, the intestinal mucosal villus structure in the fermented Sophora japonica group was restored to be comparable to that of the blank group, the inflammation was significantly reduced, and the red staining granules decreased.

[0107] 6. Effects of Fermented Liquid of Probiotics-fermented Sophora japonica on Transporter and mRNA Expression Levels in Hyperuricemic Mice

[0108] (1) Western blotting was used to detect the expression levels of URAT1, GLUT9, ABCG2, and OAT1 proteins in mouse kidneys and intestinal tissues. Protein concentration was quantified by BCA assay. SDS-PAGE and transmembrane electrophoresis were performed on 10% separating gel and 5% stacking gel. After electrophoresis, the samples were transferred to polyvinylidene fluoride membranes, blocked with 5% skim milk, incubated with primary antibodies overnight, then incubated with secondary antibodies, pictures were captured after development, and quantitative analysis of protein bands was performed using ImageJ software.

[0109] (2) Total RNA was extracted from the kidneys and jejunum using a total RNA extraction kit (Vazyme Biotech Co., Ltd., Nanjing, China). The A260 / 280 ratio was measured using an ultra-micro spectrophotometer (K5600C, Kaiao Technology, Beijing) to determine the purity of the extracted RNA. Then, cDNA was synthesized using MightyScript First Strand cDNA Synthesis Master Mix, and qPCR reactions were performed using SGExcel FastSYBR Master (Sangon Biotech Co., Ltd., Shanghai). Thermal cycling for annealing and extension was performed using a CFX96 real-time quantitative PCR instrument (Bio-Rad, USA). The specific parameter settings were as follows: 1) pre-denaturation at 95°C for 3 min; 2) denaturation at 95°C for 5 s, annealing / extension at 60°C for 20 s, for 40 cycles. Finally, the relative gene expression levels were calculated using the 2 -ΔΔCt method. The experiments were set up with three replicates. The primers involved in this experiment are shown in Table 2.

[0110] Table 2 PCR primer sequences

[0111]

[0112] (3) To determine the effects of probiotic-fermented Sophora japonica flower fermentation broth on renal uric acid reabsorption and excretion, we analyzed the expression of uric acid transporters involved in uric acid excretion and reabsorption in the kidneys and jejunum. The β-actin levels in each group did not change, and all data were normalized to β-actin. Western blotting results showed ( Figure 8 ), compared with the blank group, the expression of the uric acid reabsorption protein URAT1 in the kidneys of mice in the model group increased significantly, while there was no significant change in renal GLTU9, and the mRNA expression level was consistent with the protein expression results ( Figure 9(A) and (B) therein). After 2 weeks of intervention, compared with the model group, the expressions of GLUT9 and URAT1 in the JS4 group were significantly decreased. Allopurinol down-regulated the expression levels of GLUT9 and URAT1, while the unfermented group had no significant effect on the expression levels of GLUT9 and URAT1. On the other hand, compared with the blank group, the expression of the renal transporter OAT1 in the model group was significantly decreased, and the expression of renal ABCG2 was significantly decreased. Compared with the model group, the expression of the renal transporter ABCG2 in the JS4 group was significantly increased, which was also consistent with the results of the mRNA expression level of renal ABCG2 ( Figure 9 (C), (D) and (E) therein). The improvement effect of the expression of the transporter ABCG2 in the allopurinol group even further inhibited the expression of ABCG2 of the renal and jejunal uric acid transporters. The unfermented group had no obvious effect on the expression of ABCG2 of the renal and jejunal uric acid transporters, but had a certain increase in the expression level of the renal transporter OAT1. In summary, probiotic-fermented Sophora japonica inhibits the reabsorption of uric acid by reducing the expression of renal uric acid transporters, and increases the excretion of uric acid in the kidney and intestine by increasing the expression of renal and intestinal uric acid transporters.

[0113] 7. Effects of Active Ingredients in Probiotic-Fermented Sophora japonica

[0114] (1) The differential metabolites in Sophora japonica flowers were analyzed by non-targeted metabolomics. 200 μL of unfermented / fermented samples (Unfermented, fermented liquid of Sophora japonica flowers fermented by JS4 probiotics) were respectively taken and placed in 1.5 mL centrifuge tubes. 10 μL of internal standard (10 ppm L-2-chlorophenylalanine) and 800 μL of extraction solution (methanol:acetonitrile = 1:1, v / v) were added, and vortexed for 1 min. Subsequently, centrifuged at 4 °C and 12,000 rpm for 5 min. The supernatant was taken and centrifugally concentrated under vacuum for 4 h. 200 μL of 50% (v / v) methanol aqueous solution was added, vortexed for 40 s, and sonicated for 10 min. 200 μL of the sample was filtered through a membrane and placed in a 200 μL inner cannula for detection. Equal volumes of samples were taken from each experimental sample and mixed to serve as QC samples. Analysis was performed using a Thermo Scientific U3000 rapid liquid chromatography and a reverse-phase chromatographic column. The elution and instrument parameters are shown in Table 3. Before measuring the samples, 3 QC samples were injected first to equilibrate the chromatographic column and the mass spectrometer. The raw data was processed using metabolomics processing software Compound Discoverer (Thermo Scientific), including baseline filtering, peak identification, integration, retention time correction, peak alignment, etc., and finally a data matrix of retention time, mass-to-charge ratio, and peak intensity was obtained. The main databases include the Thermo database, public databases, and self-built databases (such as https: / / www.mzcloud.org / , http: / / www.hmdb.ca / , etc.). Then the final data matrix for subsequent analysis was obtained. Principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were analyzed using SIMCA 14.1. The quality of the OPLS-DA model is described by the R2X or R2Y and Q2 values. R2Y is defined as the proportional part of the variance in the data explained by the model and represents the degree of fitting. Q2 is defined as the proportional variance of the data predicted by the model and represents the predictability of the current model calculated by the cross-validation procedure. Differential metabolites between groups were screened according to the VIP and p values of OPLS-DA (VIP > 1, p < 0.05, FC > 1).

[0115] Table 3 Elution program and instrument parameters for non-targeted metabolomics analysis of fermented Sophora japonica flowers

[0116]

[0117] (2) We used non-targeted metabolomics technology to deeply analyze the metabolites of Sophora japonica flowers before and after fermentation, aiming to identify and quantify the key differential metabolites during fermentation. Through the overlapping display analysis of the total ion current chromatograms (TIC chromatograms) of different quality control QC sample mass spectrometry detections ( Figure 10) The results showed a high degree of overlap in the total ion current curves of metabolite detection, that is, the retention times and peak intensities were both consistent, indicating that the mass spectrometry had good signal stability when detecting the same sample at different times. The high stability of the instrument provided an important guarantee for the repeatability and reliability of the data. In positive and negative ion modes, 5724 and 3050 eigenvalues were detected respectively, among which 2244 and 1076 metabolites were annotated. By evaluating the relative standard deviation (RSD) of all ion features in the QC samples, in the positive ion mode, we found that the RSD values of 10.03% of the ion features in the QC samples were greater than 30%, while in the negative ion mode, this proportion was 4.74%. These results indicate that the metabolomics analysis method performed excellently in terms of repeatability and stability, providing a solid foundation for subsequent data analysis and biological interpretation.

[0118] To effectively extract meaningful information from these complex data, this study adopted multivariate statistical analysis methods to effectively simplify and reduce the dimension of the high-dimensional data. The similarity and difference of metabolite profiles before and after Sophora japonica fermentation were evaluated by principal component analysis (PCA), and the results are as Figure 11 shown. The PCA score plot revealed the phenomenon that the QC sample groups were closely clustered, which indicated the consistency of the metabolic profiles among the QC samples, thus confirming the stability and repeatability of the entire analysis process. In the positive ion mode, the first principal component (PC1) and the second principal component (PC2) explained 25.6% and 17.5% of the total variance respectively; while in the negative ion mode, PC1 and PC2 explained 32.9% and 19.5% of the total variance respectively. The unfermented group and the JS4-fermented Sophora japonica group showed an obvious separation trend in the PCA score plot, indicating that the fermentation process had a significant impact on the metabolites of Sophora japonica.

[0119] To further reveal the differences between groups and identify the differential metabolites between unfermented and fermented Sophora japonica, this study further adopted orthogonal partial least squares discriminant analysis (OPLS-DA) to construct a classification model. Figure 12 The OPLS-DA score plots of the unfermented group and the JS4-fermented Sophora japonica group are shown. Among them, the model parameters R2Y and Q2 values in the positive ion mode were 0.998 and 0.983 respectively, while the corresponding values in the negative ion mode were 0.999 and 0.956 respectively. The R2Y and Q2 values in all models were higher than 0.5, and this result indicated that the model had excellent predictive ability. Through 200 iterations of random permutation tests, the intercept of the Q2Y fitted regression line was less than 0, further confirming the robustness of the original model and excluding the possibility of overfitting. Combining these results, we can be confident that the established OPLS-DA model is reliable and applicable between the two comparison groups of unfermented and fermented Sophora japonica, providing a powerful analysis tool for exploring the differential metabolites between them.

[0120] In this study, a method combining T-test and partial least squares discriminant analysis (OPLS-DA) model was adopted. With the variable importance in projection (VIP) value greater than 1 and p less than 0.05 as the screening criteria, differential metabolites between unfermented and fermented sophora japonica were systematically identified. As Figure 13 shown, a total of 46 differential metabolites were identified, including 12 phenolic compounds, 8 flavonoid compounds, 10 organic acids, 2 nucleosides, 6 amino acids and their derivatives, 1 polysaccharide and its derivative (D-Mannitol 1-phosphate), and 1 fatty acid and its derivative. Figure 13 The displayed clustering heatmap reveals the abundance changes of differential metabolites between the unfermented group and the fermented group. Through cluster analysis, we observed that the samples of the unfermented group and the fermented group each clustered into independent clusters, indicating significant differences in metabolites between the two groups of samples, which is consistent with the results of principal component analysis (PCA). Metabolites with significantly increased abundance during fermentation include 23 metabolites such as Catechol, L-(+)-Lactic acid, Pyrogallol, Succinic acid, 3-(4-Hydroxyphenyl)propionic acid, Propionic acid, Ferulic acid 4-sulfate, Genistein4'-O-glucuronide, Rutin, Kaempferol 3-(6"-sulfatogentiobioside), Hispidulin, Quercetin 3-O-sulfate, Quercetin, Quercitrin, Isorhamnetin-3-O-rutinoside, etc. In numerous studies, the significant potential of phenolic and flavonoid compounds in the prevention and treatment of hyperuricemia has been fully demonstrated.

[0121] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited by the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principle of the present invention shall be equivalent replacement methods and are all included in the protection scope of the present invention.

Claims

1. A strain of Lactobacillus plantarum, characterized in that: The name is Lactiplantibacillus plantarum WH-JS4, which was deposited in the Guangdong Provincial Microbiological Culture Collection Center on the 5th floor of Building 59, No. 100 Xianlie Middle Road, Guangzhou on November 7, 2024, with the deposit number: GDMCC No: 65437.

2. Application of the plant lactobacillus according to claim 1 in sophora japonica fermentation.

3. A method for preparing a fermented sophora japonica broth for preventing and / or treating hyperuricemia, characterized in that: The steps include: (1) removing impurities from the Sophora japonica flower, drying it, crushing it, and sieving it to obtain Sophora japonica flower powder; then adding water, mixing it evenly, and sterilizing it to obtain a fermentation substrate; (2) Inoculating the plant lactobacillus described in claim 1 into a fermentation substrate, fermenting at 25-40° C., and centrifuging after the fermentation is completed to obtain a Sophora japonica fermentation liquid.

4. The method according to claim 3, characterized in that: The material-liquid ratio of the Sophora japonica powder to water in step (1) is 1 g: 10-50 mL; The inoculation amount of the plant lactobacillus described in step (2) is based on its final concentration in the fermentation system of 10 6 ~10 8 CFU / mL was added for calculation.

5. The method according to claim 4, characterized in that: The sterilization in step (1) is high temperature sterilization, the temperature is 90-121°C, and the time is 15-30 minutes; The fermentation time in step (2) is 6 to 72 hours.

6. The method according to claim 3, characterized in that: The Sophora japonica flower described in step (1) is Sophora japonica flower.

7. The method according to claim 3, characterized in that: The sieving in step (1) is through a 50-100 mesh sieve; The centrifugal conditions described in step (2) are: 4000-12000 rpm / min for 10-20 min.

8. A sophora japonica fermented liquid for preventing and / or treating hyperuricemia, characterized in that: It is prepared by the method according to any one of claims 3 to 7.

9. Use of the Lactobacillus plantarum according to claim 1 and / or the Sophora japonica fermented liquid according to claim 8 in the preparation of a product for preventing and / or treating hyperuricemia.

10. Use of the plant lactobacillus according to claim 1 and / or the sophora japonica fermented liquid according to claim 8 in the preparation of a product that inhibits xanthine oxidase.

Images